NCT07603557 Zolacaptagene Autoleucel Cold Agglutinin Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07603557 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07603557 is a hot trial to watch
Cold Agglutinin Disease is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07603557 is notable because it evaluates Zolacaptagene Autoleucel in a Phase 2 design sponsored by Juno Therapeutics, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07603557 |
| Official title | Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | Zolacaptagene Autoleucel |
| Sponsor | Juno Therapeutics, Inc. |
| Geography | United States, Denmark, United Kingdom, Germany |
| Enrollment | [object Object] |
| Primary endpoint | Cohort 1 Part A: Number of participants with treatment-emergent adverse events (TEAEs) |
| Endpoint time frame | Up to approximately Month 36 |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).
Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across United States, Denmark, United Kingdom, Germany shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Cohort 1 Part A: Number of participants with treatment-emergent adverse events (TEAEs) (Up to approximately Month 36)
- Cohort 1 Part A: Number of participants with serious AEs (SAEs) (Up to approximately Month 36)
- Cohort 1 Part A: Number of participants with AEs of special interest (AESI) (Up to approximately Month 36)
- Cohort 1 Part A: Number of participants with clinically significant laboratory abnormalities (Up to approximately Month 36)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Zolacaptagene Autoleucel is indexed as Autologous CAR-T, with target CD19, mechanism CD19 modulators, Immunologic cytotoxicity, T lymphocyte replacements, and global highest development status Phase 3.
Company & Deal Intelligence MCP profile: Juno Therapeutics, Inc. is resolved to a normalized organization record in KING COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07603557 provides a focused lens on Cold Agglutinin Disease development. Its value will be determined by whether Zolacaptagene Autoleucel can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
